It is the Ret proto-oncogene (c-Ret) is the receptor tyrosine kinase, which acts as a multi-component complex, in combination with other membrane-bound ligand-binding GDNF family of receptors (1). The ligands that bind to the Ret receptor are neurotrophic factors derived from glial cells (GDNF) as well as their congeners neurturin(neurturin), perception as well as artemin.
Studies have revealed that mutations in the Ret gene can be linked to illnesses such as papillary thyroid carcinoma as well as multiple endocrine tumors as well as familial medullary cancer, and an inherited developmental disorder called Hirschsprung's Disease. This antibody reacts with humans, mouse, rat.
The Tyr905 residue that is located within the Ret Kinase domain is a vital role in Ret biological and catalytic activities. Replacement for Phe in place of Tyr at 905 significantly reduces Ret autophosphorylation. Ret Antibody (C-3) Ret Antibody (C-33) is a top-quality monoclonal Ret antibody that can be used for identification for the Ret protein that is human-derived.
Ret Antibody (C-3) can be purchased in both the unconjugated anti-Ret antibody and also different conjugated forms of the antibody, such as agarose, HRP PE, FITC, along with various Alexa fluor (r) conjugates. The Ret proto-oncogene is structurally linked to the expanding family of tyrosine-kinase transmembrane receptors. It is also involved with GDNF signaling.
With alternative splicing, two forms that are part of the Ret proto-oncogene protein are produced. They differ from each other by having nine or 51 carboxy-terminal amino acids. The Ret genes produce two glycosylated proteins as well as in tunicamycin-treated cells the non-glycosylated protein is in line with the predicted Ret molecular weight as determined by sequence analysis.